



## **EDAP TMS SA to Announce First Quarter 2022 Financial Results on May 17, 2022**

May 10, 2022

*Company to host conference call and webcast on, Wednesday, May 18<sup>th</sup> at 8:30 am EDT*

**LYON, France, May 10, 2022** - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31<sup>st</sup>, 2022 after the markets close on Tuesday, May 17<sup>th</sup>, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Wednesday, May 18<sup>th</sup>, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

### **Conference Call & Webcast**

#### **Wednesday, May 18<sup>th</sup> @ 8:30am Eastern Time**

Domestic: 877-451-6152

International: 201-389-0879

Passcode: 13728747

Webcast: [https://viaavid.webcasts.com/starthere.jsp?ei=1541898&tp\\_key=e83b07e195](https://viaavid.webcasts.com/starthere.jsp?ei=1541898&tp_key=e83b07e195)

### **About EDAP TMS SA**

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit focalone.com, <http://www.edap-tms.com>, and [us.hifu-prostate.com](http://us.hifu-prostate.com).

### **Company contact:**

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

+33 4 72 15 31 50

[bconfort@edap-tms.com](mailto:bconfort@edap-tms.com)

### **Investor Contact**

John Fraunces

LifeSci Advisors, LLC

212-915-2568

[jfraunces@lifesciadvisors.com](mailto:jfraunces@lifesciadvisors.com)